The elevated anti-GalNAc beta IgG level of serum was shown to be associated with the significantly better survival of patients with gas-trointestinal cancer. Aim - to characterize the specificity of IgG antibodies to GalNAc beta-terminated glycans of long-term gastric cancer survivors. Serum antibodies and affinity-isolated antibodies were analysed by the indirect and competitive ELISA using glycan-polyacrylamide (PAA) conjugates as well as by isoelectric focusing and Western blotting. In the serum probes, a partial cross-reactivity of antibodies to GalNAc beta, GalNAc beta1-3Gal beta (X2i, GalNAc beta1-3GalNAc beta (PFJ and GlcNAc beta was observed. The isolated anti-GalNAc beta IgGs demonstrated the cross-reactivity to the X22i glycan mainly. The affinity of the X2i-PAA to anti-GalNAc beta IgGs was 11-21 times lower than that of the GalNAc beta-PAA. Anti-X2i and anti-PF2i IgGs demonstrated monoreactivity to their key glycans-PAA used in isolation. The IC50 values of key glycoconjugates ranged from 1 to <$E5~cdot~10 sup -7> M. No polyreactivity of antibodies to the unrelated antigens (ferritin, casein and DNA) was found. The polyclonal or oligoclonal distribution of IgG bands was established and the monoreactivity of antibodies was not associated with the clonal distribution of bands. Conclusion: the cross-reactivity of anti-GalNAc beta antibodies to X2i and related glycans deserves attention in the clarification of the role of antibodies in cancer progression and enhancement of the prognostic potential in the combined determination of antibody markers.

  Повний текст PDF - 132.678 Kb    Зміст випуску     Цитування публікації

  Якщо, ви не знайшли інформацію про автора(ів) публікації, маєте бажання виправити або відобразити більш докладну інформацію про науковців України запрошуємо заповнити "Анкету науковця"